Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Ingelheim GmbH

www.boehringer-ingelheim.com

Latest From Boehringer Ingelheim GmbH

AZ, Takeda, Novartis Praised For Medicines Access Work But More Is Needed

The 20 major companies in the Access to Medicines Index have made progress in areas like inclusive business models, R&D prioritization and equitable pricing, but not enough is being done to develop new medicines for less profitable diseases or to support flexibilities such as compulsory licensing, says a new report from the Access to Medicine Foundation.

International Pricing Strategies

Targovax Pivots Towards Oncolytic Viruses

Oncolytic virus-based therapies which act as immune activators will be the only candidates in the Norwegian biotech’s pipeline from now on.

 

Cancer ImmunoOncology

Lured By Its Discovery Platform And Pipeline, Amgen Bids For Nuevolution

Amgen offered to buy its Scandinavian discovery partner for $166.8m to gain access to Nuevolution’s DNA-encoded drug discovery platform and nascent pipeline.

Commercial Companies

Boehringer Doubles Down On Deafness With Rinri Backing

After making a move into hearing loss with an investment into Acousia Therapeutics, BI is backing a UK biotech which hopes to reverse neuropathic sensorineural hearing loss.

Ear, Nose & Throat StartUps and SMEs
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register